Fewer than 30% of health system leaders said they earned significant return on investment from virtual care offerings, ...

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...

Former Congressional Budget Office Director Dan Crippen argues the 340B discount program is overdue for reform.

Executives expect insurance coverage availability will be “largely national” by the end of 2026. The initiative is important ...

Overall, Cigna expects earnings to grow next year after posting a solid third quarter. But investments in a new PBM model and ...

Dr. Cliff Deveny announced the transition less than a month after General Catalyst finalized its $515 million acquisition of ...

The goodwill impairment charge is meant to realign Centene’s value on its own books with it value in the market, which has ...

More than 60% of respondents said insurance companies are most at fault for medical debt, compared with just 9% who blamed ...

The operator increased its outlook after posting earnings growth in the third quarter, aided by strong demand for services in ...

The company has started to score insurers on their success in making rate data available online. Large payers tend to do ...

The healthcare giant beat Wall Street expectations in the third quarter, but reported a net loss after recording a $5.7 ...

The hospital operator will invest more in organic hospital growth and high-acuity service lines as it sees strong demand for ...